U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
Vlad Poptamas
Photo source: independent.co.uk
GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the pending applications, the DEA intends to distribute regulations that govern the program of growing marijuana for scientific research under DEA registration. GB Sciences is one of just 33 companies that applied to the DEA to become registered under the Controlled Substances Act (CSA) to grow (manufacture) marijuana in order to supply DEA-registered researchers in the United States. Last week, after a three-year delay and following pressure by Congress, patients and researchers, the DEA announced that it will move forward with creating revised regulations and with reviewing the applications.
"We are well-positioned to meet and exceed the DEA's criteria, and we intend to aggressively pursue federal licensure," said Dr. Andrea Small-Howard, Chief Science Officer and Director of GB Sciences. "The sophistication of our facilities, our team's deep scientific experience, and our groundbreaking cannabinoid therapies are unparalleled inthe United States."
According to the letter from the DEA, it is looking to facilitate research, advance scientific understanding about the effects of marijuana, and potentially aid in the development of safe and effective drug products that may be approved for marketing by the Food and Drug Administration.
GB Sciences' 28,000-square-foot facility in Las Vegas, Nevada features one of the only pharmaceutical-grade "cleanroom-type" grows in the United States. The company's groundbreaking research program, led by Dr. Small-Howard with nine university research partners in the U.S. and internationally, has created a patent portfolio of cannabis-based therapies that cover over 60 disease and health conditions including Parkinson's disease, neuropathic pain, and cardiac hypertrophy.
Related Topics:Andrea Smalllatest-news
IIROC Trading Resumption – DMGI
Launch of CellPoint Digital to realise the full potential of travel companies' digital channels
Thank you for visiting my profile and thank you for reading my news and published press release!
There a many things that shape a man, but the carving is done by the hobbies and passions. I've pursued two main careers, professional photography and webdesign, while also keeping a passion for automobiles, technology and games. At PICANTE NEWS, I take care of news editing and press release publishing in se
veral categories and as I've mentioned, during my spare time, I am also a professional photographer with webdesign skills.
My future plans include developing more journalistic skills and start creating investigative journalism. You can find my reports and press release coverages in the following categories:
BANKING/FINANCIAL SERVICES, COMPUTER ELECTRONICS, AUTOMOTIVE, CONTRACTS, ANALYSIS, INTERNET TECHNOLOGY, BIOTECHNOLOGY, BLOCKCHAIN, ACQUISITIONS, RETAIL, and many more.
You can get in touch to discuss interviews or possible article submissions by contacting us.
Let's also connect via social media! You can find me on Facebook or visit my photo portfolio.
Craft coffee roasters from Poland KawePale reinforce their position in UAE at SIAL Middle East expo
Enterprise Rent-A-Car Smashes Children In Need Fundraising Target Thanks to Bespoke Donation Solution
Key figures from NASA, Air Force Research and The Aerospace Corporation to present at Small Satellites 2020
UltraSoC joins the OpenHW Group and extends its commitment to an open-source future for technology development
Kia's Bold and Biggest-Ever SUV Wows Editors with its Blend of Utility, Design and Driving Refinement
CEO retires on a high as 25 Years of the London Internet Exchange is celebrated